Equities Analysts Offer Predictions for TARA Q4 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Stock analysts at HC Wainwright upped their Q4 2025 earnings estimates for shares of Protara Therapeutics in a research report issued on Monday, November 24th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.32) per share for the quarter, up from their previous forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q1 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.70) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.34) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.60.

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $7.41 on Wednesday. The stock has a 50-day simple moving average of $5.24 and a two-hundred day simple moving average of $3.87. Protara Therapeutics has a 52-week low of $2.48 and a 52-week high of $10.48. The firm has a market capitalization of $285.93 million, a PE ratio of -4.57 and a beta of 1.59.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08.

Institutional Investors Weigh In On Protara Therapeutics

Hedge funds have recently made changes to their positions in the company. Velan Capital Investment Management LP grew its holdings in shares of Protara Therapeutics by 28.3% in the second quarter. Velan Capital Investment Management LP now owns 2,139,000 shares of the company’s stock valued at $6,481,000 after purchasing an additional 471,200 shares in the last quarter. Vanguard Group Inc. lifted its position in Protara Therapeutics by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,904,156 shares of the company’s stock valued at $8,283,000 after purchasing an additional 102,176 shares during the last quarter. Acorn Capital Advisors LLC grew its stake in shares of Protara Therapeutics by 36.9% in the 2nd quarter. Acorn Capital Advisors LLC now owns 1,752,115 shares of the company’s stock worth $5,309,000 after buying an additional 472,315 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Protara Therapeutics by 114.7% in the 2nd quarter. Geode Capital Management LLC now owns 744,519 shares of the company’s stock worth $2,256,000 after buying an additional 397,822 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Protara Therapeutics by 22.0% in the 3rd quarter. Millennium Management LLC now owns 688,256 shares of the company’s stock worth $2,994,000 after buying an additional 124,136 shares during the last quarter. 38.13% of the stock is currently owned by hedge funds and other institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.